ASCO 2017: Have Decisions by the National Institute for Health and Care Excellence Affected Outcomes of British Patients With Metastatic Castration-Resistant Prostate Cancer?
Chicago, IL (UroToday.com) John Graham gave an excellent talk regarding the role of NICE (National Institute for Health and Care Excellence) in the drug therapeutic approval process in the setting of metastatic castration-resistant prostate cancer (mCRPC). His summary of the role of NICE as it relates to the National Health Service (NHS) in England and the UK provides a nice contrast to the drug approval process here in the United States.
ASCO 2017: Intensification of Therapy for Locally Advanced and Oligometastatic Disease (Discussing Abstract 5018, 5019, 5020)
Chicago, IL (UroToday.com) Dr. Ganesh Palapattu provided the discussion for three abstracts presented at the prostate cancer poster session at the 2017 ASCO 2017 meeting. These abstracts included Abstract 5018 (Extended versus limited pelvic lymphadenectomy during radical prostatectomy for intermediate- and high-risk prostate cancer: Early outcomes from a randomized controlled phase III study)1, Abstract 5019 (Adjuvant androgen deprivation (AD) +/- mitoxantrone + prednisone (MP) in patients with high-risk prostate cancer (PC) post radical prostatectomy (RP): Phase III intergroup trial S9921)2, and Abstract 5020 (Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer).3
ASCO 2017: ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer
Chicago, IL (UroToday.com) Dr. Matthew Smith and colleagues presented the design for their trial, the ARASENS phase III trial assessing ODM-201 (darolutamide) in men with metastatic hormone-sensitive prostate cancer at the prostate cancer poster session at ASCO 2017. Even with first line therapy (ADT +/- docetaxel or abiraterone, based on the LATITUDE and STAMPEDE studies presented this week), most patients with metastatic hormone-sensitive prostate cancer (mHSPC) progress to castration-resistant prostate cancer (CRPC).
ASCO 2017: PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration
Chicago, IL (UroToday.com) The genetic landscape for men with metastatic castration resistant prostate cancer (mCRPC) is rapidly evolving. At the 2017 ASCO prostate cancer poster session, Dr. Johann De Bono and colleagues presented their phase III trial design for PROfound, an evaluation of olaparib in patients with mCRPC and a deleterious homologous recombination DNA repair aberration. There are available agents that may be offered with limited therapeutic benefit for these patients, however no molecularly stratified treatment has been approved for this heterogeneous disease.
ASCO 2017: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer
Chicago, IL (UroToday.com) Selecting the appropriate sequence and combination of therapy for metastatic castration-resistant prostate cancer (mCRPC) is challenging. At the ASCO 2017 prostate cancer poster session, Dr. Thomas Powles and colleagues presented their study design for a phase III trial comparing atezolizumab with enzalutamide versus enzalutamide alone in patients with mCRPC (IMbassador250 Trial).
ASCO 2017: Androgen deprivation therapy in the treatment of prostate cancer and dementia risk: A systematic review and meta-analysis
Chicago, IL (UroToday.com) Since the introduction of the concept of castration as a treatment for advanced or metastatic prostate cancer (PCa) by Huggins & Hodges in 1941, castration and subsequently androgen deprivation therapy (ADT) have remained the standard first-line therapy for metastatic PCa.
ASCO 2017: Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1/2 clinical trial
Chicago, IL (UroToday.com) Abiraterone acetate, a CYP17A inhibitor, is now a well-established treatment option for metastatic castration-resistant prostate cancer (mCRPC), regardless of prior docetaxel chemotherapy treatment, based on the results of the COU-AA-301 and COU-AA-302. studies.1,2 However, abiraterone administration was approved along with the administration of prednisone 5 mg twice daily, due to the risk of mineralocorticoid excess from suppression of the glucocorticoid synthesis.